In this series, ‘Genomics 101’, we go back to basics and explore some of the most important topics in genomics. In this blog, ...
On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...
Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development FTD is a devastating form of early-onset dementia that typically leads to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results